Industry News
Bionomics and Hybrigen explain their partnership
One of the more interesting collaborations between an Australian biotechnology company and a US company is the alliance between Adelaide genomics company Bionomics and proteomics company Hybrigen, based in Texas. [ + ]
Strategy to boost biotechnology's market share
A major strategy statement designed to ensure Australia becomes a stronger global competitor in the field of biotechnological research and development was launched by the CSIRO last week at the AusBiotech2002 Conference in Melbourne.
[ + ]US VC warns of early IPO dangers
Don't go public too early, use incubators to get your company off the ground and maximise collaborative opportunities, were the key messages from US venture capitalist Peter Morgan Kash at the AusBiotech 2002 conference this week. [ + ]
New technologies let researchers think outside the square
Just one in-house technology is not enough, if you're a company that's always looking for new ways to boost your drug discovery and manufacturing capabilities, delegates to this week's AusBiotech conference were told. [ + ]
Combinomics looks to sequence the unsequenceable
An Australian-developed technique for sequencing previously intractable regions of genomes is attracting increasing financial backing. [ + ]
Genetic Solutions beefed up by BIF grant
Agri-tech company Genetic Solutions will use a $250,000 Biotech Innovation Fund (BIF) grant to ride herd on a database holding more than one million samples of livestock DNA. [ + ]
Metabolic nets BIF grant for pre-clinical studies
Melbourne company Metabolic Pharmaceuticals has received a BIF grant of $234,700 to pursue pre-clinical studies on an orally available iron-chelating compound. [ + ]
We've paid the price, now let us work: Amrad boss
Gently suggesting that analysts and investors should back off and let Amrad focus on its product development, managing director Sandra Webb presented Amrad as a case study on maturing public biotechnology companies at the AusBiotech 2002 conference. [ + ]
Second BIF grant gives Protagonist an edge
For drug design start-up Protagonist, tucking a second BIF grant in as many years under its belt should help smooth future discussions with commercial partners. [ + ]
Heavy R&D spend sees Antisense book $6.3m loss
Biopharmaceutical research and development company Antisense Therapeutics reported on Wednesday a net loss of $6.3 million for the 12 months to June 30, 2002, driven largely by heavy early-stage expenditure on R&D, the company said. [ + ]
CSIRO aims to strengthen its biotech focus
CSIRO has launched a biotechnology strategy in an attempt to strengthen its focus in the field. [ + ]
IDT posts profit record number eight
Australian drug discovery company International Drug Technologies has announced a record 14 per cent jump in full year net profit to $4.2 million. [ + ]
Top scientist backs both adult and embryonic cell research
Leading scientist Catherine Verfaillie has told a briefing in Melbourne it was "unfortunate" that her work was held up as evidence that embryonic stem cell research was unnecessary. [ + ]
Circular protein research heads latest BIF grant parade
The Federal government is gambling $250,000 that Australian researchers can produce a commercial payoff from world-leading work on an unusual family of circular proteins. [ + ]
Get it together on stem cells, warns Macfarlane
Industry Minister Ian Macfarlane last night warned scientists that the real threat to the future of stem cell research in Australia was because of researchers' conflicting goals. [ + ]
